首页 > 最新文献

Blood Purification最新文献

英文 中文
Reduction Rate of Uric Acid in Blood During Continuous Renal Replacement Therapy for Acute Kidney Injury: A Multicenter Retrospective Observational Study. 急性肾损伤持续肾替代治疗期间血液中尿酸的降低率:一项多中心回顾性观察研究。
IF 2.2 3区 医学 Q3 HEMATOLOGY Pub Date : 2024-10-29 DOI: 10.1159/000542329
Yutaro Inoue, Ryota Inokuchi, Hidehiko Nakano, Yoshiki Masuda, Osamu Nishida, Kent Doi

Introduction: Continuous renal replacement therapy (CRRT) eliminates these small solutes with equal efficacy under the same conditions. However, variations in the reduction rates of these solutes observed in patients with CRRT are likely influenced by factors other than removal through CRRT. This study evaluated the reduction rates of these small solutes during CRRT and their possible association with mortality.

Methods: This study used the data of limited patients registered in the CHANGE study, which is a large retrospective observational study on CRRT management across 18 Japanese ICUs. Reduction rates of three solutes in blood, calculated on the 1st and 2nd days, were compared in patients with acute kidney injury (AKI) treated by CRRT. The potential association between solute reduction rates and mortality during CRRT or within 7 days after the termination of CRRT was evaluated.

Results: In total, 163 patients with AKI were included in the analysis. The reductuin rates of uric acid (UA) were significantly higher than those of urea and creatinine for the 1st and 2nd tests in the entire cohort. Receiver operating curve (ROC) analysis revealed that lower UA reduction rates were significantly associated with mortality during CRRT or within 7 days after CRRT termination (area under the ROC curve: 0.62 [95% confidence interval {CI} 0.52-0.71] for the 1st test and 0.63 [95%CI 0.54-0.72] for the 2nd test). After adjusting for age and SOFA score, a significant association was observed between lower UA reduction rates and hospital mortality for both tests.

Conclusion: Among the small solutes, UA reduction rates in patients with AKI treated with CRRT were notably higher than those of creatinine and urea. Furthermore, the significant association between lower UA reduction rates and mortality suggests that UA reduction rate may serve as a valuable indicator of insufficient removal of uremic solutes by CRRT, although the decline in UA production must be taken into account.

导言:在相同条件下,持续性肾脏替代疗法(CRRT)清除这些小溶质的效果相同。然而,在接受 CRRT 治疗的患者身上观察到的这些溶质减少率的变化很可能受到 CRRT 清除效果以外的其他因素的影响。本研究评估了 CRRT 期间这些小溶质的减少率及其与死亡率的可能关联:该研究是一项关于日本 18 家重症监护病房 CRRT 管理的大型回顾性观察研究。研究比较了接受 CRRT 治疗的急性肾损伤(AKI)患者第 1 天和第 2 天血液中三种溶质的减少率。评估了溶质减少率与 CRRT 期间或 CRRT 终止后 7 天内死亡率之间的潜在联系:共有 163 名 AKI 患者参与了分析。在整个队列中,尿酸(UA)的还原率明显高于尿素和肌酐的还原率。接收操作曲线(ROC)分析表明,尿酸还原率较低与 CRRT 期间或 CRRT 终止后 7 天内的死亡率显著相关(ROC 曲线下面积:0.62 [95% 置信区间(95%)]):第一次测试为 0.62 [95% 置信区间 {CI} 0.52-0.71],第二次测试为 0.63 [95%CI 0.54-0.72])。在对年龄和SOFA评分进行调整后,观察到两种测试中较低的UA降低率与住院死亡率之间存在显著关联:结论:在小溶质中,接受 CRRT 治疗的 AKI 患者的尿酸降低率明显高于肌酐和尿素。结论:在小溶质中,接受 CRRT 治疗的 AKI 患者的尿酸减少率明显高于肌酐和尿素的减少率。此外,尿酸减少率降低与死亡率之间的显著关联表明,尿酸减少率可作为 CRRT 清除尿毒症溶质不足的一个重要指标,但必须考虑到尿酸生成量的下降。
{"title":"Reduction Rate of Uric Acid in Blood During Continuous Renal Replacement Therapy for Acute Kidney Injury: A Multicenter Retrospective Observational Study.","authors":"Yutaro Inoue, Ryota Inokuchi, Hidehiko Nakano, Yoshiki Masuda, Osamu Nishida, Kent Doi","doi":"10.1159/000542329","DOIUrl":"https://doi.org/10.1159/000542329","url":null,"abstract":"<p><strong>Introduction: </strong>Continuous renal replacement therapy (CRRT) eliminates these small solutes with equal efficacy under the same conditions. However, variations in the reduction rates of these solutes observed in patients with CRRT are likely influenced by factors other than removal through CRRT. This study evaluated the reduction rates of these small solutes during CRRT and their possible association with mortality.</p><p><strong>Methods: </strong>This study used the data of limited patients registered in the CHANGE study, which is a large retrospective observational study on CRRT management across 18 Japanese ICUs. Reduction rates of three solutes in blood, calculated on the 1st and 2nd days, were compared in patients with acute kidney injury (AKI) treated by CRRT. The potential association between solute reduction rates and mortality during CRRT or within 7 days after the termination of CRRT was evaluated.</p><p><strong>Results: </strong>In total, 163 patients with AKI were included in the analysis. The reductuin rates of uric acid (UA) were significantly higher than those of urea and creatinine for the 1st and 2nd tests in the entire cohort. Receiver operating curve (ROC) analysis revealed that lower UA reduction rates were significantly associated with mortality during CRRT or within 7 days after CRRT termination (area under the ROC curve: 0.62 [95% confidence interval {CI} 0.52-0.71] for the 1st test and 0.63 [95%CI 0.54-0.72] for the 2nd test). After adjusting for age and SOFA score, a significant association was observed between lower UA reduction rates and hospital mortality for both tests.</p><p><strong>Conclusion: </strong>Among the small solutes, UA reduction rates in patients with AKI treated with CRRT were notably higher than those of creatinine and urea. Furthermore, the significant association between lower UA reduction rates and mortality suggests that UA reduction rate may serve as a valuable indicator of insufficient removal of uremic solutes by CRRT, although the decline in UA production must be taken into account.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"1-22"},"PeriodicalIF":2.2,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Residual Red Blood Cell Volume in Extracorporeal Blood Circuit after Hemodialysis: A Single-Center Study. 血液透析后体外循环中的残余红细胞容量:单中心研究
IF 2.2 3区 医学 Q3 HEMATOLOGY Pub Date : 2024-10-15 DOI: 10.1159/000542004
Sae-Yong Hong, Nam-Seon Beck, Jong-Ran Lee, Eun-Kyoung Jeon, So-Min Kim, Sol-Rim Park, Ok-Ju Park, Jungrak Hong, Joung-Il Im

Introduction: The factors contributing to blood loss during hemodialysis (HD) procedures remain underexplored. This study aimed to quantify blood loss during HD and identify the potential factors associated with it.

Methods: The study included 70 ESRD patients undergoing HD. After dialysis, the extracorporeal blood circuits were rinsed with 1,000 mL of 0.05% NH3 solution in distilled water, and hemoglobin levels were measured. Univariate regression was used to assess the linear relationship between residual red blood cell (RBC) volume and various parameters, including HD mode, dialyzer surface area, ultrafiltration goal, hypotension during HD, blood flow rate, activated partial thromboplastin time, and C-reactive protein. Multivariate regression was also conducted to explore the relationships among these parameters.

Results: The mean RBC volume remaining in the extracorporeal blood circuit after HD was 1.6 ± 0.9 mL (mode: 1.0, range: 0.3-6.5 mL). When converted to whole blood volume per patient, the mean blood volume was 5.3 ± 3.0 mL (median: 4.1 mL, mode: 4.0 mL, range: 1.0-19.0 mL). Multivariate analysis identified the dialyzer surface area as the only significant determinant of residual RBC volume.

Conclusion: After HD, the remaining RBC volume in the extracorporeal blood circuit varies from 1.6 to 6.5 mL. When the RBC volume was converted to whole blood volume for each case, the blood loss ranged from 1.0 to 19.0 mL. Dialyzer surface area was the only significant determinant of residual RBC volume.

导言:导致血液透析过程中失血的因素仍未得到充分探究。本研究旨在量化血液透析过程中的失血量,并确定与之相关的潜在因素:研究纳入了 70 名接受血液透析的 ESRD 患者。透析后,用 1,000 mL 0.05% NH3蒸馏水溶液冲洗体外血液回路,并测量血红蛋白(Hb)水平。采用单变量回归评估残余红细胞(RBC)体积与各种参数之间的线性关系,包括血液透析模式、透析器表面积、超滤目标(UFG)、血液透析过程中的低血压、血流速度、活化部分凝血活酶时间(aPTT)和 C 反应蛋白(CRP)。此外,还进行了多变量回归,以探讨这些参数之间的关系:结果:血液透析后体外血路中剩余的平均红细胞体积为 1.6 ± 0.9 毫升(模式:1.0,范围:0.3-6.5 毫升)。如果换算成每位患者的全血量,平均血量为 5.3 ± 3.0 毫升(中位数:4.1 毫升,模式:4.0 毫升,范围:1.0-19.0 毫升)。多变量分析表明,透析器表面积是决定剩余红细胞体积的唯一重要因素:结论:血液透析后,体外血路中剩余的 RBC 容量从 1.6 毫升到 6.5 毫升不等。将每个病例的 RBC 容量换算成全血容量后,失血量在 1.0 至 19.0 毫升之间。透析器表面积是决定残余 RBC 容量的唯一重要因素。
{"title":"Residual Red Blood Cell Volume in Extracorporeal Blood Circuit after Hemodialysis: A Single-Center Study.","authors":"Sae-Yong Hong, Nam-Seon Beck, Jong-Ran Lee, Eun-Kyoung Jeon, So-Min Kim, Sol-Rim Park, Ok-Ju Park, Jungrak Hong, Joung-Il Im","doi":"10.1159/000542004","DOIUrl":"10.1159/000542004","url":null,"abstract":"<p><strong>Introduction: </strong>The factors contributing to blood loss during hemodialysis (HD) procedures remain underexplored. This study aimed to quantify blood loss during HD and identify the potential factors associated with it.</p><p><strong>Methods: </strong>The study included 70 ESRD patients undergoing HD. After dialysis, the extracorporeal blood circuits were rinsed with 1,000 mL of 0.05% NH3 solution in distilled water, and hemoglobin levels were measured. Univariate regression was used to assess the linear relationship between residual red blood cell (RBC) volume and various parameters, including HD mode, dialyzer surface area, ultrafiltration goal, hypotension during HD, blood flow rate, activated partial thromboplastin time, and C-reactive protein. Multivariate regression was also conducted to explore the relationships among these parameters.</p><p><strong>Results: </strong>The mean RBC volume remaining in the extracorporeal blood circuit after HD was 1.6 ± 0.9 mL (mode: 1.0, range: 0.3-6.5 mL). When converted to whole blood volume per patient, the mean blood volume was 5.3 ± 3.0 mL (median: 4.1 mL, mode: 4.0 mL, range: 1.0-19.0 mL). Multivariate analysis identified the dialyzer surface area as the only significant determinant of residual RBC volume.</p><p><strong>Conclusion: </strong>After HD, the remaining RBC volume in the extracorporeal blood circuit varies from 1.6 to 6.5 mL. When the RBC volume was converted to whole blood volume for each case, the blood loss ranged from 1.0 to 19.0 mL. Dialyzer surface area was the only significant determinant of residual RBC volume.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"1-8"},"PeriodicalIF":2.2,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Urgent-Start Peritoneal Dialysis in Metformin-Associated Lactic Acidosis: A Critical Alternative when Immediate Hemodialysis Is Unavailable. 二甲双胍相关性乳酸酸中毒患者紧急启动腹膜透析:当无法立即进行血液透析时的关键替代方案。
IF 2.2 3区 医学 Q3 HEMATOLOGY Pub Date : 2024-10-14 DOI: 10.1159/000542003
Watanyu Parapiboon, Jakkrid Banjong, Chirakhana Siangtrong, Theerapun Boonsayomphu, Wirayut Silakun

Introduction: Intermittent hemodialysis (IHD) is a preferable renal replacement therapy (RRT) option in metformin-associated lactic acidosis (MALA) due to rapid correct metabolic acidosis. However, IHD might not be started immediately. Immediate urgent-start peritoneal dialysis (iUSPD) is used as a life-saving dialysis option and then followed by IHD. The outcomes of iUSPD were compared with other extracorporeal dialysis in MALA.

Methods: In two tertiary hospitals in Thailand, the outcomes of patients with MALA who had received three different RRT modalities (iUSPD followed by IHD, IHD, and continuous renal replacement therapy [CRRT]) from January 2015 to December 2019 were compared. The primary outcome was 30-day mortality. The secondary outcomes were door-to-dialysis time and 90-day RRT dependence.

Results: A total of 180 MALA cases that required dialysis were included (20 iUSPD, 120 IHD, and 40 CRRT). Their mean age was 64 years. Most of the patients had severe metabolic acidosis (mean pH 6.91, HCO3 6 mmol/L, and anion gap 40 mmol/L) and were critically ill. The 30-day mortality was 30% in iUSPD, 9.2% in IHD, and 32.5% in CRRT (p = 0.001). The mortality risk in the iUSPD group was not significantly different from those of the IHD and CRRT groups (adjusted HR 2.5, 95% CI: 0.65-9.6, and adjusted HR 0.75, 95% CI: 0.2-2.78, respectively). All dialysis modalities had comparable 90-day dialysis dependence. iUSPD exhibited the shortest door-to-dialysis time.

Conclusion: In MALA, iUSPD followed by IHD might be a viable RRT option to save patient lives if no other dialysis options are available.

导言间歇性血液透析(IHD)是二甲双胍相关性乳酸酸中毒(MALA)的首选肾脏替代疗法(RRT),因为它能迅速纠正代谢性酸中毒。然而,IHD 可能无法立即启动。立即紧急启动腹膜透析(iUSPD)是一种挽救生命的透析方法,然后再进行 IHD。我们对 iUSPD 与其他体外透析在 MALA 中的效果进行了比较。方法 在泰国的两家三级医院,比较了 2015 年 1 月至 2019 年 12 月期间接受三种不同 RRT 模式(iUSPD 后 IHD、IHD 和持续肾脏替代疗法 [CRRT])的 MALA 患者的治疗效果。主要结果是 30 天死亡率。次要结果是门到透析时间和 90 天 RRT 依赖性。结果 纳入了 180 例需要透析的 MALA 病例(20 例 iUSPD、120 例 IHD 和 40 例 CRRT)。他们的平均年龄为 64 岁。大多数患者患有严重的代谢性酸中毒(平均 pH 值为 6.91,HCO3 为 6 mmol/L,阴离子间隙为 40 mmol/L),病情危重。iUSPD 患者的 30 天死亡率为 30%,IHD 患者为 9.2%,CRRT 患者为 32.5%(P = 0.001)。iUSPD 组的死亡风险与 IHD 组和 CRRT 组无明显差异(调整后 HR 分别为 2.5,95% CI 0.65-9.6 和 0.75,95% CI 0.2-2.78)。所有透析方式的 90 天透析依赖性相当,iUSPD 的门到透析时间最短。结论 在 MALA 中,如果没有其他透析方案,iUSPD 后 IHD 可能是挽救患者生命的可行 RRT 方案。
{"title":"Urgent-Start Peritoneal Dialysis in Metformin-Associated Lactic Acidosis: A Critical Alternative when Immediate Hemodialysis Is Unavailable.","authors":"Watanyu Parapiboon, Jakkrid Banjong, Chirakhana Siangtrong, Theerapun Boonsayomphu, Wirayut Silakun","doi":"10.1159/000542003","DOIUrl":"10.1159/000542003","url":null,"abstract":"<p><strong>Introduction: </strong>Intermittent hemodialysis (IHD) is a preferable renal replacement therapy (RRT) option in metformin-associated lactic acidosis (MALA) due to rapid correct metabolic acidosis. However, IHD might not be started immediately. Immediate urgent-start peritoneal dialysis (iUSPD) is used as a life-saving dialysis option and then followed by IHD. The outcomes of iUSPD were compared with other extracorporeal dialysis in MALA.</p><p><strong>Methods: </strong>In two tertiary hospitals in Thailand, the outcomes of patients with MALA who had received three different RRT modalities (iUSPD followed by IHD, IHD, and continuous renal replacement therapy [CRRT]) from January 2015 to December 2019 were compared. The primary outcome was 30-day mortality. The secondary outcomes were door-to-dialysis time and 90-day RRT dependence.</p><p><strong>Results: </strong>A total of 180 MALA cases that required dialysis were included (20 iUSPD, 120 IHD, and 40 CRRT). Their mean age was 64 years. Most of the patients had severe metabolic acidosis (mean pH 6.91, HCO3 6 mmol/L, and anion gap 40 mmol/L) and were critically ill. The 30-day mortality was 30% in iUSPD, 9.2% in IHD, and 32.5% in CRRT (p = 0.001). The mortality risk in the iUSPD group was not significantly different from those of the IHD and CRRT groups (adjusted HR 2.5, 95% CI: 0.65-9.6, and adjusted HR 0.75, 95% CI: 0.2-2.78, respectively). All dialysis modalities had comparable 90-day dialysis dependence. iUSPD exhibited the shortest door-to-dialysis time.</p><p><strong>Conclusion: </strong>In MALA, iUSPD followed by IHD might be a viable RRT option to save patient lives if no other dialysis options are available.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anticoagulation Strategies for Continuous Renal Replacement Therapy in France: A Survey of Practices. 法国持续性肾脏替代疗法的抗凝策略:实践调查。
IF 2.2 3区 医学 Q3 HEMATOLOGY Pub Date : 2024-09-30 DOI: 10.1159/000540553
Justine Pible, Frank Bidar, Nicolas Chardon, Valérie Cerro, Carole Ichai, Céline Monard, Antoine Schneider, Olivier Joannes-Boyau, Jean-Michel Constantin, Thomas Rimmelé

Introduction: Anticoagulation for continuous renal replacement therapy (CRRT) can be performed using systemic anticoagulation or regional citrate anticoagulation (RCA). The 2012 Kidney Disease Improving Global Outcomes guidelines support the use of RCA as the first-line strategy in patients requiring CRRT, with and without bleeding risk. Implementing RCA in the intensive care unit (ICU) implies involving all medical and nursing staff. The primary objective of this study was to report and describe the various anticoagulation strategies for CRRT in French ICUs. The secondary objectives were to determine the rate of RCA use and to identify the factors limiting its implementation.

Methods: An online questionnaire containing 40 questions was sent to attending physicians and fellows practicing in French ICUs between May and September 2021. The questionnaire was sent via several networks: mailing list from the French Society of Anesthesia and Intensive Care Medicine and mailing lists of RRT manufacturers.

Results: A total of 597 responses were analyzed. RCA was used by most of the participants for patients with (81%) and without (80%) increased bleeding risk. The preferred CRRT modality of the participants while using RCA was continuous veno-venous hemodialysis (48%). The clinical situations frequently reported as an absolute contraindication to RCA were uncontrolled shock associated with liver failure and drug poisoning impairing citrate metabolism (62% and 52%, respectively). In case of a higher risk of citrate accumulation, most participants claimed to perform closer biological monitoring (57%) or to modify the CRRT protocol (61%). Among the participants who did not prescribe RCA as a first-line strategy, the main factors limiting its implementation were the lack of nurse (50%) or physician (34%) training.

Conclusion: RCA is the main anticoagulation strategy prescribed for CRRT in France. Providing medical and nursing staff easy access to training may facilitate the understanding and use of RCA as the first-line anticoagulation strategy for CRRT.

简介:连续性肾脏替代治疗(CRRT)的抗凝可采用全身抗凝或区域性枸橼酸盐抗凝(RCA)。2012 年《肾脏病改善全球疗效指南》支持将 RCA 作为需要进行 CRRT 的患者的一线治疗策略,无论患者有无出血风险。在重症监护病房(ICU)实施 RCA 意味着需要所有医护人员的参与。本研究的主要目的是报告和描述法国重症监护病房中 CRRT 的各种抗凝策略。次要目标是确定 RCA 的使用率,并找出限制其实施的因素:在 2021 年 5 月至 9 月期间,向法国重症监护病房的主治医师和研究员发送了一份包含 40 个问题的在线调查问卷。问卷通过几个网络发送:法国麻醉和重症监护医学会的邮件列表以及 RRT 制造商的邮件列表:结果:共分析了 597 份回复。大多数参与者对有出血风险(81%)和无出血风险(80%)的患者使用 RCA。参与者在使用 RCA 时首选的 CRRT 方式是连续性静脉-静脉血液透析(48%)。作为 RCA 绝对禁忌症的常见临床情况是与肝功能衰竭相关的未控制休克和影响枸橼酸盐代谢的药物中毒(分别占 62% 和 52%)。在枸橼酸盐蓄积风险较高的情况下,大多数参与者声称要进行更严密的生物监测(57%)或修改 CRRT 方案(61%)。在未将 RCA 作为一线策略处方的参与者中,限制其实施的主要因素是缺乏护士(50%)或医生(34%)培训:结论:RCA 是法国 CRRT 的主要抗凝策略。结论:在法国,RCA 是 CRRT 的主要抗凝策略。为医护人员提供便捷的培训途径可促进他们了解并使用 RCA 作为 CRRT 的一线抗凝策略。.
{"title":"Anticoagulation Strategies for Continuous Renal Replacement Therapy in France: A Survey of Practices.","authors":"Justine Pible, Frank Bidar, Nicolas Chardon, Valérie Cerro, Carole Ichai, Céline Monard, Antoine Schneider, Olivier Joannes-Boyau, Jean-Michel Constantin, Thomas Rimmelé","doi":"10.1159/000540553","DOIUrl":"10.1159/000540553","url":null,"abstract":"<p><strong>Introduction: </strong>Anticoagulation for continuous renal replacement therapy (CRRT) can be performed using systemic anticoagulation or regional citrate anticoagulation (RCA). The 2012 Kidney Disease Improving Global Outcomes guidelines support the use of RCA as the first-line strategy in patients requiring CRRT, with and without bleeding risk. Implementing RCA in the intensive care unit (ICU) implies involving all medical and nursing staff. The primary objective of this study was to report and describe the various anticoagulation strategies for CRRT in French ICUs. The secondary objectives were to determine the rate of RCA use and to identify the factors limiting its implementation.</p><p><strong>Methods: </strong>An online questionnaire containing 40 questions was sent to attending physicians and fellows practicing in French ICUs between May and September 2021. The questionnaire was sent via several networks: mailing list from the French Society of Anesthesia and Intensive Care Medicine and mailing lists of RRT manufacturers.</p><p><strong>Results: </strong>A total of 597 responses were analyzed. RCA was used by most of the participants for patients with (81%) and without (80%) increased bleeding risk. The preferred CRRT modality of the participants while using RCA was continuous veno-venous hemodialysis (48%). The clinical situations frequently reported as an absolute contraindication to RCA were uncontrolled shock associated with liver failure and drug poisoning impairing citrate metabolism (62% and 52%, respectively). In case of a higher risk of citrate accumulation, most participants claimed to perform closer biological monitoring (57%) or to modify the CRRT protocol (61%). Among the participants who did not prescribe RCA as a first-line strategy, the main factors limiting its implementation were the lack of nurse (50%) or physician (34%) training.</p><p><strong>Conclusion: </strong>RCA is the main anticoagulation strategy prescribed for CRRT in France. Providing medical and nursing staff easy access to training may facilitate the understanding and use of RCA as the first-line anticoagulation strategy for CRRT.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"1-8"},"PeriodicalIF":2.2,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142340992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel Method to Monitor Arteriovenous Fistula Maturation: Impact on Catheter Residence Time. 监测动静脉瘘成熟的新方法:对导管停留时间的影响。
IF 2.2 3区 医学 Q3 HEMATOLOGY Pub Date : 2024-09-26 DOI: 10.1159/000540306
Laura Rosales Merlo, Xiaoling Ye, Hanjie Zhang, Brenda Chan, Marilou Mateo, Seth Johnson, Frank M van der Sande, Jeroen P Kooman, Peter Kotanko

Introduction: Arteriovenous fistula (AVF) maturation assessment is essential to reduce venous catheter residence. We introduced central venous oxygen saturation (ScvO2) and estimated upper body blood flow (eUBBF) to monitor newly created fistula maturation and recorded catheter time in patients with and without ScvO2-based fistula maturation.

Methods: From 2017 to 2019, we conducted a multicenter quality improvement project (QIP) in hemodialysis patients with the explicit goal to shorten catheter residence time post-AVF creation through ScvO2-based maturation monitoring. In patients with a catheter as vascular access, we tracked ScvO2 and eUBBF pre- and post-AVF creation. The primary outcome was catheter residence time post-AVF creation. We compared catheter residence time post-AVF creation between QIP patients and controls. One control group comprised concurrent patients; a second control group comprised historic controls (2014-2016). We conducted Kaplan-Meier analysis and constructed a Cox proportional hazards model with variables adjustment to assess time-to-catheter removal.

Results: The QIP group comprised 44 patients (59 ± 17 years), the concurrent control group 48 patients (59 ± 16 years), the historic control group 57 patients (58 ± 15 years). Six-month post-AVF creation, the fraction of non-censored patients with catheter in place was 21% in the QIP cohort, 67% in the concurrent control group, and 68% in the historic control group. In unadjusted and adjusted analysis, catheter residence time post-fistula creation was shorter in QIP patients compared to either control groups (p < 0.001).

Conclusion: ScvO2-based assessment of fistula maturation is associated with shorter catheter residence post-AVF creation.

导言 动脉-静脉瘘(AVF)成熟度评估对于减少静脉导管停留时间至关重要。我们引入了中心静脉血氧饱和度(ScvO2)和估算的上半身血流量(eUBBF)来监测新建立的瘘管成熟度,并记录了有和没有基于 ScvO2 的瘘管成熟度的患者的导管时间。方法 从 2017 年到 2019 年,我们在血液透析患者中开展了一项多中心质量改进项目(QIP),其明确目标是通过基于 ScvO2 的成熟度监测缩短 AVF 创建后的导管停留时间。在使用导管作为血管通路的患者中,我们跟踪了建立无创血管通路前后的 ScvO2 和 eUBBF。主要结果是导管在 AVF 创建后的停留时间。我们比较了 QIP 患者和对照组在建立无创动脉导管后的导管停留时间。一个对照组由同期患者组成,第二个对照组由历史对照组(2014-2016 年)组成。我们进行了卡普兰-梅耶尔分析,并构建了带变量调整的考克斯比例危险模型,以评估导管移除时间。结果 QIP 组有 44 名患者(59±17 岁),同期对照组有 48 名患者(59±16 岁),历史对照组有 57 名患者(58±15 岁)。在建立无创静脉输液系统后六个月,QIP 组中导管在位的非删节患者比例为 21%,同期对照组为 67%,历史对照组为 68%。在未调整和调整后的分析中,QIP 患者在瘘管创建后的导管停留时间短于任一对照组(P<0.001)。结论 基于 ScvO2 的瘘管成熟度评估与 AVF 创建后导管停留时间缩短有关。
{"title":"Novel Method to Monitor Arteriovenous Fistula Maturation: Impact on Catheter Residence Time.","authors":"Laura Rosales Merlo, Xiaoling Ye, Hanjie Zhang, Brenda Chan, Marilou Mateo, Seth Johnson, Frank M van der Sande, Jeroen P Kooman, Peter Kotanko","doi":"10.1159/000540306","DOIUrl":"10.1159/000540306","url":null,"abstract":"<p><strong>Introduction: </strong>Arteriovenous fistula (AVF) maturation assessment is essential to reduce venous catheter residence. We introduced central venous oxygen saturation (ScvO2) and estimated upper body blood flow (eUBBF) to monitor newly created fistula maturation and recorded catheter time in patients with and without ScvO2-based fistula maturation.</p><p><strong>Methods: </strong>From 2017 to 2019, we conducted a multicenter quality improvement project (QIP) in hemodialysis patients with the explicit goal to shorten catheter residence time post-AVF creation through ScvO2-based maturation monitoring. In patients with a catheter as vascular access, we tracked ScvO2 and eUBBF pre- and post-AVF creation. The primary outcome was catheter residence time post-AVF creation. We compared catheter residence time post-AVF creation between QIP patients and controls. One control group comprised concurrent patients; a second control group comprised historic controls (2014-2016). We conducted Kaplan-Meier analysis and constructed a Cox proportional hazards model with variables adjustment to assess time-to-catheter removal.</p><p><strong>Results: </strong>The QIP group comprised 44 patients (59 ± 17 years), the concurrent control group 48 patients (59 ± 16 years), the historic control group 57 patients (58 ± 15 years). Six-month post-AVF creation, the fraction of non-censored patients with catheter in place was 21% in the QIP cohort, 67% in the concurrent control group, and 68% in the historic control group. In unadjusted and adjusted analysis, catheter residence time post-fistula creation was shorter in QIP patients compared to either control groups (p < 0.001).</p><p><strong>Conclusion: </strong>ScvO2-based assessment of fistula maturation is associated with shorter catheter residence post-AVF creation.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142341001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
e-Prescribing, Charting, and Documentation for Continuous Renal Replacement Therapy: A Green Intensive Care Unit and Nephrology Initiative. 电子处方、病历和 CRRT 文档;绿色重症监护室和肾病学倡议。
IF 2.2 3区 医学 Q3 HEMATOLOGY Pub Date : 2024-09-19 DOI: 10.1159/000541487
Ian Baldwin, Jian Wen Chan, Stuart Downs, Connor Palmer

Background: Patient care informatics are becoming more advanced with digital capacity and server functionality. The intensive care unit (ICU) is becoming paperless for prescribing, charting, and monitoring care. A further challenge is to include all life sustaining therapies in this digital space. Digital modules and options may be available; however, continuous renal replacement therapies (CRRTs) often require custom design for many nuances. Associated with the COVID pandemic and a surge in the paperless and "green" ICU bedside, we gathered a team to design, develop, and implement a CRRT orders, charting-documentation, and monitoring functionality into our existing Cerner (ORACLE Corp., Austin, Texas, USA) software.

Key messages: This included new approaches to the two-dimensional paper documents used prior and a live dashboard with new metrics and data. The design linked to other relevant CRRT pages such as the master patient fluid balance, pathology results, and medication prescribing. The primary views and function are role-related for medical, nursing, and pharmacy with specific and sensitive input. Following the build and implementation, initial evaluation was positive and led to an audit trail or e-history for prescribers use and provision for concurrent therapies. Clinicians use this digital ordering differently with live data available for "handover" and case discussion. There is scope for research and further links to devices such as personal phones and via an app.

Summary: This experience may assist CRRT users design and develop similar prescribing, charting, and monitoring bedside computer opportunities in the desire for digital and green nephrology in the ICU.

背景:随着数字容量和服务器功能的发展,病人护理信息学正变得越来越先进。重症监护病房(ICU)的处方、病历和监控护理工作正在实现无纸化。另一个挑战是将所有维持生命的疗法纳入这一数字化空间。数字模块和选项可能是可用的,但连续性肾脏替代疗法(CRRT)通常需要定制设计,以满足许多细微差别的要求。随着 COVID 的流行以及无纸化和 "绿色 "重症监护病房床旁的兴起,我们组建了一个团队,在现有的 Cerner(ORACLE 公司,美国德克萨斯州奥斯汀)软件中设计、开发并实施了 CRRT 订单、图表记录和监控功能:关键信息:这包括对以前使用的二维纸质文档采用新的方法,以及采用新指标和数据的实时仪表板。该设计与其他相关的 CRRT 页面相连接,例如主病人体液平衡、病理结果和药物处方。主要视图和功能与医疗、护理和药房的角色相关,具有特定和敏感的输入。在建立和实施之后,初步评估结果是积极的,为开药者提供了审计跟踪或电子历史记录,并提供了并发疗法。临床医生以不同的方式使用这种数字订购方式,并提供实时数据用于 "交接 "和病例讨论。小结:这一经验可以帮助 CRRT 用户设计和开发类似的处方、制表和床旁计算机监控功能,从而实现在重症监护病房开展数字化和绿色肾脏病学的愿望。
{"title":"e-Prescribing, Charting, and Documentation for Continuous Renal Replacement Therapy: A Green Intensive Care Unit and Nephrology Initiative.","authors":"Ian Baldwin, Jian Wen Chan, Stuart Downs, Connor Palmer","doi":"10.1159/000541487","DOIUrl":"10.1159/000541487","url":null,"abstract":"<p><strong>Background: </strong>Patient care informatics are becoming more advanced with digital capacity and server functionality. The intensive care unit (ICU) is becoming paperless for prescribing, charting, and monitoring care. A further challenge is to include all life sustaining therapies in this digital space. Digital modules and options may be available; however, continuous renal replacement therapies (CRRTs) often require custom design for many nuances. Associated with the COVID pandemic and a surge in the paperless and \"green\" ICU bedside, we gathered a team to design, develop, and implement a CRRT orders, charting-documentation, and monitoring functionality into our existing Cerner (ORACLE Corp., Austin, Texas, USA) software.</p><p><strong>Key messages: </strong>This included new approaches to the two-dimensional paper documents used prior and a live dashboard with new metrics and data. The design linked to other relevant CRRT pages such as the master patient fluid balance, pathology results, and medication prescribing. The primary views and function are role-related for medical, nursing, and pharmacy with specific and sensitive input. Following the build and implementation, initial evaluation was positive and led to an audit trail or e-history for prescribers use and provision for concurrent therapies. Clinicians use this digital ordering differently with live data available for \"handover\" and case discussion. There is scope for research and further links to devices such as personal phones and via an app.</p><p><strong>Summary: </strong>This experience may assist CRRT users design and develop similar prescribing, charting, and monitoring bedside computer opportunities in the desire for digital and green nephrology in the ICU.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142280093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum. 勘误。
IF 2.2 3区 医学 Q3 HEMATOLOGY Pub Date : 2024-09-19 DOI: 10.1159/000541224
{"title":"Erratum.","authors":"","doi":"10.1159/000541224","DOIUrl":"10.1159/000541224","url":null,"abstract":"","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"1"},"PeriodicalIF":2.2,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142280094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is endovascular arteriovenous fistula a feasible alternative for hemodialysis patients? 血管内动静脉瘘是血液透析患者的可行替代方案吗?
IF 3 3区 医学 Q3 HEMATOLOGY Pub Date : 2024-09-12 DOI: 10.1159/000541233
Hugo Vergara-Pérez,Raúl Diaitz-Usetxi Laplaza,Alejandro Pérez Alba,Pablo Baliño Remiro,Asunción Rius Peris,M Ángeles Fenollosa Segarra,Alejandro Tamayo Vasquez,Javier Reque
INTRODUCTIONFor hemodialysis (HD) patients, the selection of vascular access (VA) is a crucial factor that significantly affects morbidity and mortality. Historically, native Arteriovenous Fistulas (AVFs) have been established using surgical techniques. However, devices facilitating percutaneous endovascular arteriovenous fistula formation have recently been introduced in clinical practice, showing promising initial evidence. The primary objectives were technical success, efficacy, and cannulation rates. The secondary objectives included primary and cumulative patency, safety, and the number of procedures required to maintain fistula patency.METHODSA prospective, single-center, single-arm study that included all patients who underwent endovascular arteriovenous fistulas (endoAVF) creation using the WavelinQ™ EndoAVF System at a University Hospital between December 2021 and August 2023.RESULTSA total of 20 patients who underwent an endoAVF were included. Technical success was 100%. 75% (15) of the endoAVFs met the criteria for physiological suitability. The cannulation rate was 66% (10/15) for endoAVFs that reached physiological suitability. At 6 months of follow-up, the primary and cumulative patency rates were 65% and 75%, respectively; at 12 months, these were 50% and 70%, respectively. Serious adverse events were not observed. The reintervention rate was 0.33 procedures/patient-year.CONCLUSIONBased on our experience, creating AVFs using the WavelinQ 4-F EndoAVF system is safe and effective, with high technical success rates and acceptable patency and reintervention rates.
导言对于血液透析(HD)患者来说,血管通路(VA)的选择是一个关键因素,对发病率和死亡率有重大影响。一直以来,原生动静脉瘘(AVF)都是通过外科技术建立的。然而,最近临床实践中出现了促进经皮血管内动静脉瘘形成的设备,并显示出良好的初步效果。研究的首要目标是技术成功率、疗效和插管率。方法该研究是一项前瞻性、单中心、单臂研究,纳入了 2021 年 12 月至 2023 年 8 月期间在一家大学医院使用 WavelinQ™ EndoAVF 系统进行血管内动静脉瘘(endoAVF)成形术的所有患者。结果共纳入了 20 名进行血管内动静脉瘘成形术的患者。技术成功率为 100%。75%(15 例)的腔内腹腔引流符合生理适宜性标准。达到生理适宜标准的内腔静脉输液的插管率为 66%(10/15)。随访 6 个月时,主要通畅率和累积通畅率分别为 65% 和 75%;随访 12 个月时,主要通畅率和累积通畅率分别为 50% 和 70%。未观察到严重不良事件。结论根据我们的经验,使用 WavelinQ 4-F EndoAVF 系统创建 AVF 安全有效,技术成功率高,通畅率和再介入率均可接受。
{"title":"Is endovascular arteriovenous fistula a feasible alternative for hemodialysis patients?","authors":"Hugo Vergara-Pérez,Raúl Diaitz-Usetxi Laplaza,Alejandro Pérez Alba,Pablo Baliño Remiro,Asunción Rius Peris,M Ángeles Fenollosa Segarra,Alejandro Tamayo Vasquez,Javier Reque","doi":"10.1159/000541233","DOIUrl":"https://doi.org/10.1159/000541233","url":null,"abstract":"INTRODUCTIONFor hemodialysis (HD) patients, the selection of vascular access (VA) is a crucial factor that significantly affects morbidity and mortality. Historically, native Arteriovenous Fistulas (AVFs) have been established using surgical techniques. However, devices facilitating percutaneous endovascular arteriovenous fistula formation have recently been introduced in clinical practice, showing promising initial evidence. The primary objectives were technical success, efficacy, and cannulation rates. The secondary objectives included primary and cumulative patency, safety, and the number of procedures required to maintain fistula patency.METHODSA prospective, single-center, single-arm study that included all patients who underwent endovascular arteriovenous fistulas (endoAVF) creation using the WavelinQ™ EndoAVF System at a University Hospital between December 2021 and August 2023.RESULTSA total of 20 patients who underwent an endoAVF were included. Technical success was 100%. 75% (15) of the endoAVFs met the criteria for physiological suitability. The cannulation rate was 66% (10/15) for endoAVFs that reached physiological suitability. At 6 months of follow-up, the primary and cumulative patency rates were 65% and 75%, respectively; at 12 months, these were 50% and 70%, respectively. Serious adverse events were not observed. The reintervention rate was 0.33 procedures/patient-year.CONCLUSIONBased on our experience, creating AVFs using the WavelinQ 4-F EndoAVF system is safe and effective, with high technical success rates and acceptable patency and reintervention rates.","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":"1 1","pages":"1-15"},"PeriodicalIF":3.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142260782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of hypophosphatemia during continuous kidney replacement therapy and clinical outcomes: a systematic review and meta-analysis. 持续肾脏替代治疗期间低磷血症与临床结果的关系:系统回顾和荟萃分析。
IF 3 3区 医学 Q3 HEMATOLOGY Pub Date : 2024-09-12 DOI: 10.1159/000541423
Lu Jin,Peiyun Li,Qing Xv,Linshen Xie,Ling Zhang
INTRODUCTIONHypophosphatemia is a common and potentially severe complication of continuous kidney replacement therapy (CKRT), but the evidence on the correlation between hypophosphatemia occurring during CKRT and clinical outcomes remains limited.METHODSElectronic databases (PubMed, Embase, Web of Science, and the Cochrane database) were searched from inception to March 1, 2024. All possible studies that examined the following outcomes were included: all-cause mortality, mechanical ventilation, intensive care unit (ICU) stay, and CKRT duration.RESULTSA total of 8,631 patients from eight cohort studies were included. There was no statistical association between hypophosphatemia during CKRT and all-cause mortality in critically ill patients (OR 0.82, 95% CI 0.57-1.18, P =0.28, I2 = 83%). However, hypophosphatemia was associated with longer duration of mechanical ventilation (WMD 80.30h, 95% CI 31.37-129.22, P =0.001, I2 = 60%). Furthermore, a longer length of ICU stay (WMD 2.76d, 95% CI 2.50-3.02, P <0.00001, I2 = 36%) and CKRT duration (WMD 51.51h, 95% CI 2.69-100.34, P =0.04, I2 = 96%) were observed in patients with hypophosphatemia.CONCLUSIONSThe association between hypophosphatemia and mortality in patients receiving CKRT was insufficient. However, hypophosphatemia during CKRT might be associated with adverse clinical outcomes for critically ill patients.
引言低磷血症是持续性肾脏替代治疗(CKRT)的一种常见且潜在的严重并发症,但有关 CKRT 期间发生的低磷血症与临床结果之间相关性的证据仍然有限。方法检索了从开始到 2024 年 3 月 1 日的电子数据库(PubMed、Embase、Web of Science 和 Cochrane 数据库)。结果共纳入了 8 项队列研究中的 8631 名患者。CKRT期间的低磷血症与重症患者的全因死亡率之间没有统计学关联(OR 0.82,95% CI 0.57-1.18,P =0.28,I2 =83%)。然而,低磷血症与机械通气时间延长有关(WMD 80.30h,95% CI 31.37-129.22,P =0.001,I2 =60%)。此外,在低磷血症患者中还观察到更长的 ICU 住院时间(WMD 2.76d,95% CI 2.50-3.02,P <0.00001,I2 = 36%)和 CKRT 持续时间(WMD 51.51h,95% CI 2.69-100.34,P =0.04,I2 = 96%)。然而,CKRT期间的低磷血症可能与危重病人的不良临床结果有关。
{"title":"Association of hypophosphatemia during continuous kidney replacement therapy and clinical outcomes: a systematic review and meta-analysis.","authors":"Lu Jin,Peiyun Li,Qing Xv,Linshen Xie,Ling Zhang","doi":"10.1159/000541423","DOIUrl":"https://doi.org/10.1159/000541423","url":null,"abstract":"INTRODUCTIONHypophosphatemia is a common and potentially severe complication of continuous kidney replacement therapy (CKRT), but the evidence on the correlation between hypophosphatemia occurring during CKRT and clinical outcomes remains limited.METHODSElectronic databases (PubMed, Embase, Web of Science, and the Cochrane database) were searched from inception to March 1, 2024. All possible studies that examined the following outcomes were included: all-cause mortality, mechanical ventilation, intensive care unit (ICU) stay, and CKRT duration.RESULTSA total of 8,631 patients from eight cohort studies were included. There was no statistical association between hypophosphatemia during CKRT and all-cause mortality in critically ill patients (OR 0.82, 95% CI 0.57-1.18, P =0.28, I2 = 83%). However, hypophosphatemia was associated with longer duration of mechanical ventilation (WMD 80.30h, 95% CI 31.37-129.22, P =0.001, I2 = 60%). Furthermore, a longer length of ICU stay (WMD 2.76d, 95% CI 2.50-3.02, P &lt;0.00001, I2 = 36%) and CKRT duration (WMD 51.51h, 95% CI 2.69-100.34, P =0.04, I2 = 96%) were observed in patients with hypophosphatemia.CONCLUSIONSThe association between hypophosphatemia and mortality in patients receiving CKRT was insufficient. However, hypophosphatemia during CKRT might be associated with adverse clinical outcomes for critically ill patients.","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":"47 1","pages":"1-18"},"PeriodicalIF":3.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142260783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Dialysis on Structural Brain Connectivity in Patients with End-Stage Renal Disease. 透析对终末期肾病患者大脑结构连通性的影响。
IF 2.2 3区 医学 Q3 HEMATOLOGY Pub Date : 2024-09-05 DOI: 10.1159/000541239
Byeongo Choi, Chang Min Heo, Jiyae Yi, Dong Ah Lee, Yoo Jin Lee, Sihyung Park, Yang Wook Kim, Junghae Ko, Bong Soo Park, Kang Min Park

Introduction: Patients with end-stage renal disease (ESRD) are known to have reduced structural and functional brain connectivity in the brain regions associated with cognitive function. However, the effect of dialysis on brain connectivity remains unclear. This study aimed to evaluate the effects of dialysis on structural brain connectivity in patients with ESRD.

Methods: This prospective study included 20 patients with ESRD in the pre-dialysis stage and 35 healthy controls. The patients underwent T2-weighted and three-dimensional T1-weighted magnetic resonance imaging before and 3 months after dialysis initiation. Moreover, the cortical thickness was calculated. We applied graph theoretical analysis to calculate the structural covariance network based on cortical thickness. We compared the cortical thickness and structural covariance network of patients with ESRD in the pre-dialysis stage with those of healthy controls and with those of patients with ESRD in the post-dialysis stage.

Results: The mean cortical thickness in both hemispheres was lower in patients with ESRD in the pre-dialysis stage than in healthy controls (2.296 vs. 2.354, p = 0.030; 2.282 vs. 2.362, p = 0.004, respectively) and was higher in patients with ESRD in the post-dialysis stage than in those in the pre-dialysis stage (2.333 vs. 2.296, p = 0.001; 2.322 vs. 2.282, p = 0.002, respectively). Analysis of the structural covariance network revealed that the assortative coefficient was lower in patients with ESRD in the pre-dialysis stage than in healthy controls (-0.062 vs. -0.031, p = 0.029) and was higher in patients with ESRD in the post-dialysis stage than in those in the pre-dialysis stage (-0.002 vs. -0.062, p = 0.042).

Conclusion: We observed differences in the cortical thickness and structural covariance networks before and after dialysis in patients with ESRD. This indicates that dialysis affects structural brain connectivity, contributing to the understanding of the pathophysiological mechanism of cognitive function alterations resulting from dialysis in patients with ESRD.

简介众所周知,终末期肾病(ESRD)患者与认知功能相关的脑区的结构和功能性脑连接性降低。然而,透析对大脑连接性的影响仍不清楚。本研究旨在评估透析对 ESRD 患者大脑结构连通性的影响:这项前瞻性研究纳入了 20 名处于透析前期的 ESRD 患者和 35 名健康对照者。患者在开始透析前和透析后 3 个月分别接受了 T2 加权和三维 T1 加权磁共振成像检查。此外,我们还计算了皮质厚度。我们应用图论分析计算了基于皮质厚度的结构协方差网络。我们比较了透析前阶段 ESRD 患者与健康对照组以及透析后阶段 ESRD 患者的皮质厚度和结构协方差网络:透析前ESRD患者两个半球的平均皮质厚度低于健康对照组(分别为2.296 vs. 2.354,p=0.030;2.282 vs. 2.362,p=0.004),而透析后ESRD患者两个半球的平均皮质厚度高于透析前ESRD患者(分别为2.333 vs. 2.296,p=0.001;2.322 vs. 2.282,p=0.002)。结构协方差网络分析显示,透析前阶段的ESRD患者的同位系数低于健康对照组(-0.062 vs. -0.031,p=0.029),透析后阶段的ESRD患者的同位系数高于透析前阶段的患者(-0.002 vs. -0.062,p=0.042):我们观察到透析前后 ESRD 患者大脑皮层厚度和结构协方差网络的差异。结论:我们观察到透析前后 ESRD 患者大脑皮层厚度和结构协方差网络的差异,这表明透析会影响大脑结构连通性,有助于了解 ESRD 患者透析导致认知功能改变的病理生理机制。.
{"title":"Effect of Dialysis on Structural Brain Connectivity in Patients with End-Stage Renal Disease.","authors":"Byeongo Choi, Chang Min Heo, Jiyae Yi, Dong Ah Lee, Yoo Jin Lee, Sihyung Park, Yang Wook Kim, Junghae Ko, Bong Soo Park, Kang Min Park","doi":"10.1159/000541239","DOIUrl":"10.1159/000541239","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with end-stage renal disease (ESRD) are known to have reduced structural and functional brain connectivity in the brain regions associated with cognitive function. However, the effect of dialysis on brain connectivity remains unclear. This study aimed to evaluate the effects of dialysis on structural brain connectivity in patients with ESRD.</p><p><strong>Methods: </strong>This prospective study included 20 patients with ESRD in the pre-dialysis stage and 35 healthy controls. The patients underwent T2-weighted and three-dimensional T1-weighted magnetic resonance imaging before and 3 months after dialysis initiation. Moreover, the cortical thickness was calculated. We applied graph theoretical analysis to calculate the structural covariance network based on cortical thickness. We compared the cortical thickness and structural covariance network of patients with ESRD in the pre-dialysis stage with those of healthy controls and with those of patients with ESRD in the post-dialysis stage.</p><p><strong>Results: </strong>The mean cortical thickness in both hemispheres was lower in patients with ESRD in the pre-dialysis stage than in healthy controls (2.296 vs. 2.354, p = 0.030; 2.282 vs. 2.362, p = 0.004, respectively) and was higher in patients with ESRD in the post-dialysis stage than in those in the pre-dialysis stage (2.333 vs. 2.296, p = 0.001; 2.322 vs. 2.282, p = 0.002, respectively). Analysis of the structural covariance network revealed that the assortative coefficient was lower in patients with ESRD in the pre-dialysis stage than in healthy controls (-0.062 vs. -0.031, p = 0.029) and was higher in patients with ESRD in the post-dialysis stage than in those in the pre-dialysis stage (-0.002 vs. -0.062, p = 0.042).</p><p><strong>Conclusion: </strong>We observed differences in the cortical thickness and structural covariance networks before and after dialysis in patients with ESRD. This indicates that dialysis affects structural brain connectivity, contributing to the understanding of the pathophysiological mechanism of cognitive function alterations resulting from dialysis in patients with ESRD.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Blood Purification
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1